Gapping up
In reaction to strong earnings/guidance: PERI +11.7%, FTR +5.7%, NTP +5.1%, ARRY +3.1%, CAMT +2.8%, SHLD +1.1%, ON +0.7%, DO +0.7%, HSBC +0.6%, .
M&A news: GAI +85% (receives preliminary non-binding 'Going Private' offer for shares of the company for $8.75/share), PRE +2.1% (reaches a definitive agreement with EXOR S.p.A. (EXOSF) to be acquired for $140.50/share), NICE +0.9% (divests its Physical Security business unit to Battery Ventures for potential value of up to $100 mln; also issues guidance)
Other news: LXRX +26.8% (Lexicon Pharma and Ipsen (IPSEY) report positive results from TELESTAR Phase 3 Study; meets primary endpoint), OSUR +11.1% (receives US FDA Emergency Use Authorization, for its OraQuick Ebola Rapid antigen test for use with fingerstick and venous whole blood ), BVXV +10.1% (announces 3 year followup, statistical analysis of results from a study of BVX-005), FIT +3.6% (cont vol post IPO), ISIS +1.9% (ISIS Pharm and AstraZeneca (AZN) enter into strategic collaboration to discover and develop antisense therapies for cardiovascular, metabolic and renal disease), UN +1.7% (still checking), PTN +1.3% (files for ~18.63 mln share common stock offering by selling shareholders), GPRO +1% (cont strength)
Analyst comments: MBLY +3.2% (hearing positive note from MS), AIZ +1.4% (upgraded to Buy from Underperform at BofA/Merrill), RAS +1% (upgraded to Buy from Neutral at Ladenburg Thalmann), AMCX +0.9% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
In reaction to strong earnings/guidance: PERI +11.7%, FTR +5.7%, NTP +5.1%, ARRY +3.1%, CAMT +2.8%, SHLD +1.1%, ON +0.7%, DO +0.7%, HSBC +0.6%, .
M&A news: GAI +85% (receives preliminary non-binding 'Going Private' offer for shares of the company for $8.75/share), PRE +2.1% (reaches a definitive agreement with EXOR S.p.A. (EXOSF) to be acquired for $140.50/share), NICE +0.9% (divests its Physical Security business unit to Battery Ventures for potential value of up to $100 mln; also issues guidance)
Other news: LXRX +26.8% (Lexicon Pharma and Ipsen (IPSEY) report positive results from TELESTAR Phase 3 Study; meets primary endpoint), OSUR +11.1% (receives US FDA Emergency Use Authorization, for its OraQuick Ebola Rapid antigen test for use with fingerstick and venous whole blood ), BVXV +10.1% (announces 3 year followup, statistical analysis of results from a study of BVX-005), FIT +3.6% (cont vol post IPO), ISIS +1.9% (ISIS Pharm and AstraZeneca (AZN) enter into strategic collaboration to discover and develop antisense therapies for cardiovascular, metabolic and renal disease), UN +1.7% (still checking), PTN +1.3% (files for ~18.63 mln share common stock offering by selling shareholders), GPRO +1% (cont strength)
Analyst comments: MBLY +3.2% (hearing positive note from MS), AIZ +1.4% (upgraded to Buy from Underperform at BofA/Merrill), RAS +1% (upgraded to Buy from Neutral at Ladenburg Thalmann), AMCX +0.9% (upgraded to Overweight from Equal-Weight at Morgan Stanley)